Last reviewed · How we verify
Minzasolmin tablet formulation under fasting condition
At a glance
| Generic name | Minzasolmin tablet formulation under fasting condition |
|---|---|
| Also known as | UCB0599 |
| Sponsor | UCB Biopharma SRL |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Dry eye
- Dyspepsia
- Dry mouth
- Headache
- Dizziness postural
- Nausea
- Asthenia
- Allergy to arthropod bite
- Arthralgia
- Head discomfort
- Oropharyngeal pain
- Haematoma
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: